Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $78.63.
據Marketbeat.com報道，埃南塔製藥公司(納斯達克代碼：ENTA-GET Rating)的股票獲得了涵蓋該公司的九家評級公司的共識建議，即“適度買入”。四位研究分析師對該股的評級為持有建議，四位分析師給該公司指定了買入建議。過去一年對該股進行評級的經紀商的平均12個月目標價為78.63美元。
A number of equities research analysts recently weighed in on ENTA shares. Oppenheimer increased their price target on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a "market perform" rating in a research note on Wednesday, August 10th. StockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. Evercore ISI raised Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 price objective on the stock in a report on Wednesday, July 6th. JMP Securities upped their price objective on Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a "market outperform" rating in a report on Tuesday, August 9th. Finally, Royal Bank of Canada decreased their price objective on Enanta Pharmaceuticals from $67.00 to $66.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 9th.
許多股票研究分析師最近紛紛買入Enta的股票。8月10日，週三，奧本海默在一份研究報告中將他們對Enanta PharmPharmticals的目標價從53.00美元上調至59.00美元，並給予該公司“市場表現”評級。在8月10日星期三的一份研究報告中，StockNews.com將Enanta PharmPharmticals的評級從“賣出”上調至“持有”。Evercore ISI在7月6日(星期三)的一份報告中將Enanta PharmPharmticals的評級從“在線”上調至“表現優於大盤”，併為該股設定了62.00美元的目標價。JMP證券在8月9日週二的一份報告中將Enanta PharmPharmticals的目標價從103.00美元上調至137.00美元，並給予該公司“市場表現優於大盤”的評級。最後，加拿大皇家銀行在8月9日(星期二)的一份報告中將他們對Enanta PharmPharmticals的目標價從67.00美元下調至66.00美元，並對該股設定了“行業表現”評級。
Enanta Pharmaceuticals Trading Down 0.1 %
Enanta製藥公司股價下跌0.1%
ENTA opened at $52.65 on Friday. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $102.00. The stock's fifty day simple moving average is $60.55 and its 200 day simple moving average is $58.09. The stock has a market cap of $1.09 billion, a PE ratio of -8.98 and a beta of 0.55.
Enta上週五開盤報52.65美元。Enanta PharmPharmticals的一年低點為37.59美元，一年高點為102.00美元。該股的50日簡單移動均線為60.55美元，200日簡單移動均線為58.09美元。該股市值為10.9億美元，市盈率為-8.98，貝塔係數為0.55。
Hedge Funds Weigh In On Enanta Pharmaceuticals
對衝基金買入Enanta製藥
Large investors have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $68,633,000. State Street Corp raised its position in shares of Enanta Pharmaceuticals by 29.9% during the second quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company's stock worth $80,332,000 after acquiring an additional 390,842 shares during the last quarter. Deep Track Capital LP bought a new stake in Enanta Pharmaceuticals in the first quarter worth approximately $14,146,000. Invesco Ltd. increased its holdings in Enanta Pharmaceuticals by 173.0% in the fourth quarter. Invesco Ltd. now owns 289,844 shares of the biotechnology company's stock worth $21,674,000 after purchasing an additional 183,676 shares in the last quarter. Finally, Darwin Global Management Ltd. bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth approximately $12,428,000. 97.09% of the stock is currently owned by institutional investors.
大型投資者最近買賣了該公司的股票。Ra Capital Management L.P.在第一季度購買了價值約6863.3萬美元的Enanta製藥公司的新股票頭寸。道富集團在第二季度將其在Enanta PharmPharmticals的股票頭寸提高了29.9%。道富集團目前持有這家生物技術公司1,699,428股股票，價值80,332,000美元，此前該公司在上個季度又收購了390,842股。Deep Track Capital LP在第一季度購買了Enanta PharmPharmticals的新股份，價值約14,146,000美元。景順在第四季度增持了173.0%的Enanta PharmPharmticals股份。景順公司目前持有289,844股這家生物技術公司的股票，價值21,674,000美元，上個季度又購買了183,676股。最後，達爾文全球管理有限公司在第四季度購買了價值約12,428,000美元的Enanta製藥公司的新股份。97.09%的股票目前由機構投資者持有。
About Enanta Pharmaceuticals
關於Enanta製藥公司
(Get Rating)
(獲取評級)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta製藥公司是一家生物技術公司，發現和開發用於治療病毒感染和肝病的小分子藥物。其研發的疾病靶標包括呼吸道合胞病毒、SARS-CoV-2、人類偏肺病毒和乙肝病毒。該公司與雅培簽訂了一項合作開發和許可協議，以識別、開發和商業化丙型肝炎病毒NS3和NS3/4A蛋白酶抑制劑化合物，包括用於治療慢性丙型肝炎病毒的paritaprevir和glecapvir。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免費獲取StockNews.com關於Enanta製藥公司(Enta)的研究報告
- 這些機構持有達頓餐飲國際公司的股份
- 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎？
- 住房建設的黃金時代已經結束了嗎？
- 這三大股利支付者也擁有強勁的價格增長
- 天然氣價格繼續回升，這些股票應該會受益
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Enanta製藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Enanta製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。